These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. BRAF V600E immunohistochemistry is reliable in primary and metastatic colorectal carcinoma regardless of treatment status and shows high intratumoral homogeneity. Bledsoe JR; Kamionek M; Mino-Kenudson M Am J Surg Pathol; 2014 Oct; 38(10):1418-28. PubMed ID: 24921639 [TBL] [Abstract][Full Text] [Related]
3. Deficient DNA mismatch repair is associated with favorable prognosis in Thai patients with sporadic colorectal cancer. Korphaisarn K; Pongpaibul A; Limwongse C; Roothumnong E; Klaisuban W; Nimmannit A; Jinawath A; Akewanlop C World J Gastroenterol; 2015 Jan; 21(3):926-34. PubMed ID: 25624727 [TBL] [Abstract][Full Text] [Related]
4. Detection of the BRAF V600E mutation in colon carcinoma: critical evaluation of the imunohistochemical approach. Lasota J; Kowalik A; Wasag B; Wang ZF; Felisiak-Golabek A; Coates T; Kopczynski J; Gozdz S; Miettinen M Am J Surg Pathol; 2014 Sep; 38(9):1235-41. PubMed ID: 24832158 [TBL] [Abstract][Full Text] [Related]
5. Improved molecular classification of serrated lesions of the colon by immunohistochemical detection of BRAF V600E. Mesteri I; Bayer G; Meyer J; Capper D; Schoppmann SF; von Deimling A; Birner P Mod Pathol; 2014 Jan; 27(1):135-44. PubMed ID: 23887306 [TBL] [Abstract][Full Text] [Related]
6. Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma. Adackapara CA; Sholl LM; Barletta JA; Hornick JL Histopathology; 2013 Aug; 63(2):187-93. PubMed ID: 23763264 [TBL] [Abstract][Full Text] [Related]
7. Immunohistochemistry with Anti-BRAF V600E (VE1) Mouse Monoclonal Antibody is a Sensitive Method for Detection of the BRAF V600E Mutation in Colon Cancer: Evaluation of 120 Cases with and without KRAS Mutation and Literature Review. Dvorak K; Higgins A; Palting J; Cohen M; Brunhoeber P Pathol Oncol Res; 2019 Jan; 25(1):349-359. PubMed ID: 29127628 [TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical detection of BRAF V600E mutant protein using the VE1 antibody in colorectal carcinoma is highly concordant with molecular testing but requires rigorous antibody optimization. Kuan SF; Navina S; Cressman KL; Pai RK Hum Pathol; 2014 Mar; 45(3):464-72. PubMed ID: 24529329 [TBL] [Abstract][Full Text] [Related]
9. Assessment of BRAF V600E Status in Colorectal Carcinoma: Tissue-Specific Discordances between Immunohistochemistry and Sequencing. Estrella JS; Tetzlaff MT; Bassett RL; Patel KP; Williams MD; Curry JL; Rashid A; Hamilton SR; Broaddus RR Mol Cancer Ther; 2015 Dec; 14(12):2887-95. PubMed ID: 26438153 [TBL] [Abstract][Full Text] [Related]
10. Ultra-deep sequencing confirms immunohistochemistry as a highly sensitive and specific method for detecting BRAF V600E mutations in colorectal carcinoma. Rössle M; Sigg M; Rüschoff JH; Wild PJ; Moch H; Weber A; Rechsteiner MP Virchows Arch; 2013 Nov; 463(5):623-31. PubMed ID: 24085553 [TBL] [Abstract][Full Text] [Related]
11. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer. Capper D; Voigt A; Bozukova G; Ahadova A; Kickingereder P; von Deimling A; von Knebel Doeberitz M; Kloor M Int J Cancer; 2013 Oct; 133(7):1624-30. PubMed ID: 23553055 [TBL] [Abstract][Full Text] [Related]
12. A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer. Day F; Muranyi A; Singh S; Shanmugam K; Williams D; Byrne D; Pham K; Palmieri M; Tie J; Grogan T; Gibbs P; Sieber O; Waring P; Desai J Target Oncol; 2015 Mar; 10(1):99-109. PubMed ID: 24859797 [TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions. Busam KJ; Hedvat C; Pulitzer M; von Deimling A; Jungbluth AA Am J Surg Pathol; 2013 Mar; 37(3):413-20. PubMed ID: 23211290 [TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical detection of the BRAF V600E mutant protein in colorectal cancers in Taiwan is highly concordant with the molecular test. Hang JF; Li AF; Chang SC; Liang WY Histopathology; 2016 Jul; 69(1):54-62. PubMed ID: 26588428 [TBL] [Abstract][Full Text] [Related]
15. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency. Dawson H; Galván JA; Helbling M; Muller DE; Karamitopoulou E; Koelzer VH; Economou M; Hammer C; Lugli A; Zlobec I Int J Cancer; 2014 May; 134(10):2342-51. PubMed ID: 24166180 [TBL] [Abstract][Full Text] [Related]
16. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506 [TBL] [Abstract][Full Text] [Related]
17. BRAFV600E mutation analysis by immunohistochemistry in patients with thoracic metastases from colorectal cancer. Ilie MI; Long-Mira E; Hofman V; Mouroux J; Vignaud JM; Gauchotte G; Begueret H; Merlio JP; Emile JF; Hébuterne X; Hofman P Pathology; 2014 Jun; 46(4):311-5. PubMed ID: 24798160 [TBL] [Abstract][Full Text] [Related]
18. Immunohistochemistry with the anti-BRAF V600E (VE1) antibody: impact of pre-analytical conditions and concordance with DNA sequencing in colorectal and papillary thyroid carcinoma. Dvorak K; Aggeler B; Palting J; McKelvie P; Ruszkiewicz A; Waring P Pathology; 2014 Oct; 46(6):509-17. PubMed ID: 25014730 [TBL] [Abstract][Full Text] [Related]